EGFR and mTOR as therapeutic targets in glioblastoma
- The quest for new and improved therapies for glioblastoma (GB) has been mostly unsuccessful in more than a decade despite significant efforts. The few exceptions include the optimization of classical alkylating chemotherapy by including lomustine in the first line regimen for GB with a methylated MGMT promoter and tumor treating fields. The GB signaling network has been well-characterized and genetic alterations resulting in activation of receptor tyrosine kinases and especially epidermal growth factor receptor (EGFR) and downstream mammalian target of rapamycin complex 1 (mTORC1) signaling were found in the majority of GBs. ...
Download full text files
Additional Services
| Author: | Michael Wilfried RonellenfitschORCiDGND, Anna-Luisa LugerORCiD, Joachim Peter SteinbachORCiDGND |
|---|---|
| URN: | urn:nbn:de:hebis:30:3-507611 |
| DOI: | https://doi.org/10.18632/oncotarget.27094 |
| ISSN: | 1949-2553 |
| Pubmed Id: | https://pubmed.ncbi.nlm.nih.gov/31413813 |
| Parent Title (English): | OncoTarget |
| Publisher: | Impact Journals LLC |
| Place of publication: | [s. l.] |
| Document Type: | Article |
| Language: | English |
| Year of Completion: | 2019 |
| Date of first Publication: | 2019/07/30 |
| Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
| Release Date: | 2019/08/22 |
| Tag: | DDIT4; EGFR; glioblastoma; mTOR; tumor microenvironment |
| Volume: | 10 |
| Issue: | 46 |
| Page Number: | 3 |
| First Page: | 4721 |
| Last Page: | 4723 |
| Note: | All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License. |
| HeBIS-PPN: | 453774466 |
| Institutes: | Medizin / Medizin |
| Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
| Sammlungen: | Universitätspublikationen |
| Licence (German): |  Creative Commons - Namensnennung 3.0 |
